文章：

检查点抑制剂免疫治疗生物标志物的发展前景

The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy

原文发布日期：2019-02-12

DOI: 10.1038/s41568-019-0116-x

类型: Review Article

开放获取: 否

英文摘要：

Checkpoint inhibitor-based immunotherapies that target cytotoxic T lymphocyte antigen 4 (CTLA4) or the programmed cell death 1 (PD1) pathway have achieved impressive success in the treatment of different cancer types. Yet, only a subset of patients derive clinical benefit. It is thus critical to understand the determinants driving response, resistance and adverse effects. In this Review, we discuss recent work demonstrating that immune checkpoint inhibitor efficacy is affected by a combination of factors involving tumour genomics, host germline genetics, PD1 ligand 1 (PDL1) levels and other features of the tumour microenvironment, as well as the gut microbiome. We focus on recently identified molecular and cellular determinants of response. A better understanding of how these variables cooperate to affect tumour–host interactions is needed to optimize the implementation of precision immunotherapy.

摘要翻译： 

基于检查点抑制剂的免疫疗法，靶向细胞毒性T淋巴细胞抗原4（CTLA4）或程序性细胞死亡1（PD1）通路，在不同类型癌症治疗中取得了显著成功。然而，仅部分患者能获得临床获益。因此，理解驱动治疗反应、耐药性及不良反应的决定因素至关重要。本综述讨论了近期研究，证明免疫检查点抑制剂的疗效受多种因素共同影响，包括肿瘤基因组学、宿主种系遗传学、PD1配体1（PDL1）水平、肿瘤微环境特征以及肠道微生物组。我们重点关注近期发现的治疗反应的分子与细胞决定因素。需更深入理解这些变量如何协同影响肿瘤-宿主相互作用，以优化精准免疫治疗的实践。

原文链接：

The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy